309 related articles for article (PubMed ID: 15003647)
1. A Plasmodium falciparum GLURP-MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies.
Theisen M; Soe S; Brunstedt K; Follmann F; Bredmose L; Israelsen H; Madsen SM; Druilhe P
Vaccine; 2004 Mar; 22(9-10):1188-98. PubMed ID: 15003647
[TBL] [Abstract][Full Text] [Related]
2. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants.
Carvalho LJ; Alves FA; Bianco C; Oliveira SG; Zanini GM; Soe S; Druilhe P; Theisen M; Muniz JA; Daniel-Ribeiro CT
Clin Diagn Lab Immunol; 2005 Feb; 12(2):242-8. PubMed ID: 15699417
[TBL] [Abstract][Full Text] [Related]
3. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design.
Singh S; Soe S; Mejia JP; Roussilhon C; Theisen M; Corradin G; Druilhe P
J Infect Dis; 2004 Sep; 190(5):1010-8. PubMed ID: 15295710
[TBL] [Abstract][Full Text] [Related]
4. Age-dependent systemic antibody responses and immunisation-associated changes in mice orally and nasally immunised with Lactococcus lactis expressing a malaria parasite protein.
Moorthy SA; Yasawardena SG; Ramasamy R
Vaccine; 2009 Aug; 27(36):4947-52. PubMed ID: 19545652
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of synthetic peptides derived from Plasmodium falciparum proteins.
Zerpa NC; Wide A; Noda J; Bermúdez H; Pabón R; Noya OO
Exp Parasitol; 2006 Aug; 113(4):227-34. PubMed ID: 16513113
[TBL] [Abstract][Full Text] [Related]
7. Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.
Amoah LE; Nuvor SV; Obboh EK; Acquah FK; Asare K; Singh SK; Boampong JN; Theisen M; Williamson KC
Parasit Vectors; 2017 Aug; 10(1):395. PubMed ID: 28835262
[TBL] [Abstract][Full Text] [Related]
8. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
[TBL] [Abstract][Full Text] [Related]
9. Glutamate rich Plasmodium falciparum antigen (GLURP).
Høgh B; Thompson R; Zakiuddin IS; Boudin C; Borre M
Parassitologia; 1993 Jul; 35 Suppl():47-50. PubMed ID: 8233611
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
[TBL] [Abstract][Full Text] [Related]
12. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
Hermsen CC; Verhage DF; Telgt DS; Teelen K; Bousema JT; Roestenberg M; Bolad A; Berzins K; Corradin G; Leroy O; Theisen M; Sauerwein RW
Vaccine; 2007 Apr; 25(15):2930-40. PubMed ID: 16914240
[TBL] [Abstract][Full Text] [Related]
13. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels.
Carvalho LJ; Oliveira SG; Theisen M; Alves FA; Andrade MC; Zanini GM; Brígido MC; Oeuvray C; Póvoa MM; Muniz JA; Druilhe P; Daniel-Ribeiro CT
Scand J Immunol; 2004 Apr; 59(4):363-72. PubMed ID: 15049780
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
15. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
Mamo H; Esen M; Ajua A; Theisen M; Mordmüller B; Petros B
Malar J; 2013 Feb; 12():51. PubMed ID: 23383869
[TBL] [Abstract][Full Text] [Related]
16. Plasmodium falciparum malaria in children aged 0-2 years: the role of foetal haemoglobin and maternal antibodies to two asexual malaria vaccine candidates (MSP3 and GLURP).
Kangoye DT; Nebie I; Yaro JB; Debe S; Traore S; Ouedraogo O; Sanou G; Soulama I; Diarra A; Tiono A; Marsh K; Sirima SB; Bejon P
PLoS One; 2014; 9(9):e107965. PubMed ID: 25238160
[TBL] [Abstract][Full Text] [Related]
17. A recombinant hybrid protein as antigen for an anti-blood stage malaria vaccine.
Knapp B; Hundt E; Enders B; Küpper HA
Behring Inst Mitt; 1991 Feb; (88):147-56. PubMed ID: 2049032
[TBL] [Abstract][Full Text] [Related]
18. Antibody response profiles induced by Plasmodium falciparum glutamate-rich protein in naturally exposed individuals from a Brazilian area endemic for malaria.
Pratt-Riccio LR; Lima-Junior JC; Carvalho LJ; Theisen M; Espíndola-Mendes EC; Santos F; Oliveira-Ferreira J; Goldberg AC; Daniel-Ribeiro CT; Banic DM
Am J Trop Med Hyg; 2005 Dec; 73(6):1096-103. PubMed ID: 16354819
[TBL] [Abstract][Full Text] [Related]
19. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.
Chang SP; Nikaido CM; Hashimoto AC; Hashiro CQ; Yokota BT; Hui GS
J Immunol; 1994 Apr; 152(7):3483-90. PubMed ID: 8144929
[TBL] [Abstract][Full Text] [Related]
20. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
